Nalaganje...
Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy
Direct-acting antiviral (DAA) therapy has changed the landscape of hepatitis C virus (HCV) management and has changed the focus to the possibility of HCV elimination in the near future. Glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, have addressed many of the exi...
Shranjeno v:
| izdano v: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6681154/ https://ncbi.nlm.nih.gov/pubmed/31534310 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S172512 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|